After finishing at $22.68 in the prior trading day, Myriad Genetics Inc. (NASDAQ: MYGN) closed at $22.94, up 1.15%. In other words, the price has increased by $+0.26 from its previous closing price. On the day, 753760 shares were traded. MYGN stock price reached its highest trading level at $23.23 during the session, while it also had its lowest trading level at $22.07.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Sponsored
Ratios:
Our goal is to gain a better understanding of MYGN by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.70 and its Current Ratio is at 1.80. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 27 when Lambert Nicole sold 6,433 shares for $23.48 per share. The transaction valued at 151,047 led to the insider holds 240,506 shares of the business.
Riggsbee Richard Bryan sold 15,000 shares of MYGN for $338,253 on Mar 02. The Chief Financial Officer now owns 337,885 shares after completing the transaction at $22.55 per share. On Mar 02, another insider, Lambert Nicole, who serves as the Chief Operating Officer of the company, sold 13,184 shares for $22.74 each. As a result, the insider received 299,823 and left with 215,220 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MYGN now has a Market Capitalization of 1.72B and an Enterprise Value of 1.80B. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.61 while its Price-to-Book (P/B) ratio in mrq is 2.23. Its current Enterprise Value per Revenue stands at 2.60 whereas that against EBITDA is -17.19.
Stock Price History:
Over the past 52 weeks, MYGN has reached a high of $28.18, while it has fallen to a 52-week low of $13.92. The 50-Day Moving Average of the stock is 21.66, while the 200-Day Moving Average is calculated to be 20.38.
Shares Statistics:
The stock has traded on average 614.21K shares per day over the past 3-months and 479.13k shares per day over the last 10 days, according to various share statistics. A total of 81.30M shares are outstanding, with a floating share count of 79.43M. Insiders hold about 3.00% of the company’s shares, while institutions hold 102.49% stake in the company. Shares short for MYGN as of May 14, 2023 were 3.77M with a Short Ratio of 3.68M, compared to 3.74M on Apr 13, 2023. Therefore, it implies a Short% of Shares Outstanding of 4.63% and a Short% of Float of 6.65%.
Earnings Estimates
Its stock is currently analyzed by 8 different market analysts. On average, analysts expect EPS of -$0.08 for the current quarter, with a high estimate of $0 and a low estimate of -$0.12, while EPS last year was $0.04. The consensus estimate for the next quarter is -$0.07, with high estimates of -$0.02 and low estimates of -$0.14.
Analysts are recommending an EPS of between -$0.25 and -$0.37 for the fiscal current year, implying an average EPS of -$0.32. EPS for the following year is $0.07, with 10 analysts recommending between $0.28 and -$0.13.
Revenue Estimates
9 analysts predict $187.04M in revenue for the current quarter. It ranges from a high estimate of $189.94M to a low estimate of $185M. As of the current estimate, Myriad Genetics Inc.’s year-ago sales were $179.3M, an estimated increase of 4.30% from the year-ago figure. For the next quarter, 9 analysts are estimating revenue of $180.39M, an increase of 6.00% over than the figure of $4.30% in the same quarter last year. There is a high estimate of $188M for the next quarter, whereas the lowest estimate is $174.6M.
A total of 10 analysts have provided revenue estimates for MYGN’s current fiscal year. The highest revenue estimate was $746.98M, while the lowest revenue estimate was $738M, resulting in an average revenue estimate of $742.08M. In the same quarter a year ago, actual revenue was $678.4M, up 9.40% from the average estimate. Based on 10 analysts’ estimates, the company’s revenue will be $800.11M in the next fiscal year. The high estimate is $809.3M and the low estimate is $784.35M. The average revenue growth estimate for next year is up 7.80% from the average revenue estimate for this year.
